

Comments on the ACD Received from the Public Through the NICE Website

Name	Dr I B Chaudhry
Role	NHS Professional
Other role	Hon Senior Lecturer University of Manchester
Location	England
Conflict	No
Notes	"I have received support from BMS, Lilly, Astrazeneca & Janssen to: - Travel to international conferences - Advisory boards - Chair and speak at regional, national and international meetings"
Comments on individual sections of the ACD:	
Section 1 (Appraisal Committee's preliminary recommendations)	<p>I am the Lead Consultant for Lancashire Care Early Intervention Service (14 -35 yrs), with 3 adult consultant psychiatrists and on CAMHS consultant psychiatrist. We also have seperate inpatient units for 14-16 yrs old and 16-18 yrs old.</p> <p>In my view clinical scale are useful to quantify outcomes but impact on quality of life and social functioning are more important.</p> <p>Aripiprazole is one of the 4 most commonly prescribed antipsychotics to clients in our service.</p> <p>Data on tolerability is extremely important and aripiprazole has the edge having lower propensity for weight gain and sexual dysfunction.</p>
Section 2 (the technology)	<p>"I generally use smaller doses of aripiprazole, starting 5ms on alternate days (it has a long half life) for 1-2 weeks, then 5 mgs daili and then according to clinical response.</p> <p>The liquid form is an advantage for smaller doses."</p>
Section 3 (manufacturer's submission)	<p>"The data submitted by manufacturers of the drug is required but for me most important is my/our own experience.</p> <p>We find aripiprazole to be clinically as efficacious as any other antipsychotic with better tolerability profile."</p>
Section 4 (consideration of the evidence)	<p>"I disagree that risperidone is the most commonly prescribe antipsychotic.</p> <p>We recently completed an audit on prescribing practice in our service, looking at about 200 records. Olanzapine was the most frequently prescribed antipsychotic followed by aripiprazole and qutiepine."</p>
Section 5 (implementation)	In my opinion aripiprazole should be licensed for the younger age group.

Section 6 (proposed recommendations for further research)	NICE should consider involving clinicians working in Early Intervention Services and using their experience in formulating decisions.
Section 7 (related NICE guidance)	
Section 8 (proposed date of review of guidance)	
Date	27/09/2010 15:58

Name	a
Role	NHS Professional
Other role	
Location	England
Conflict	No
Notes	
Comments on individual sections of the ACD:	
Section 1 (Appraisal Committee's preliminary recommendations)	
Section 2 (the technology)	
Section 3 (manufacturer's submission)	
Section 4 (consideration of the evidence)	
Section 5 (implementation)	
Section 6 (proposed recommendations for further research)	
Section 7 (related NICE guidance)	
Section 8 (proposed date of review of guidance)	
Date	29/09/2010 14:46